Thilo Zander
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova V, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). EClinicalMedicine 2023; 64:102221.
22.09.2023Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
22.09.2023EClinicalMedicine 2023; 64:102221
Novak Urban, Fehr Martin, Schär Sämi, Dreyling Martin, Schmidt Christian, Derenzini Enrico, Zander Thilo, Hess Georg, Mey Ulrich J M, Ferrero Simone, Mach Nicolas, Boccomini Carola, Böttcher Sebastian, Voegeli Michèle, Cairoli Anne, Ivanova Vanesa-Sindi, Menter Thomas, Dirnhofer Stefan, Scheibe Bernhard, Gadient Sandra, Eckhardt Katrin, Zucca Emanuele, Driessen Christoph, Renner Christoph
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia 2023; 37:699-701.
12.01.2023Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
12.01.2023Leukemia 2023; 37:699-701
Zander Thilo, Pabst Thomas, Schär Sämi, Aebi Stefan, Mey Ulrich J M, Novak Urban, Lerch Erika, Rhyner Agocs Gaëlle, Goede Jeroen, Maniecka Zuzanna, Hayoz Stefanie, Rüfer Axel, Renner Christoph, Driessen Christoph
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Sonneveld P, Driessen C, Pour L, Levin M, Bos G, Ypma P, Wu K, van de Velden V, Oliva S, Broijl A, Croockewit A, Boccadoro M, Spencer A, Palumbo G, Offidani M, van de Donk N, Hveding C, Waage A, Minnema M, Troia R, Cornelisse P, Zamagni E, Zander T, Zweegman S, Ludwig H, Aquino S, van der Holt B, Beksac M, Dimopoulos M, Wester R, Hájek R, Gulbrandsen N, Gregersen H, Morelli A, De Rosa L, Cafro A, Gay F, Dozza L, Pantani L, Cavo M. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. J Clin Oncol 2021; 39:3613-3622.
14.09.2021Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
14.09.2021J Clin Oncol 2021; 39:3613-3622
Sonneveld Pieter, Driessen Christoph, Pour Luca, Levin Mark-David, Bos Gerard, Ypma Paula F, Wu KaLung, van de Velden Vincent, Oliva Stefania, Broijl Annemiek, Croockewit Alexandra, Boccadoro Mario, Spencer Andrew, Palumbo Giuseppe A, Offidani Massimo, van de Donk Niels W C J, Hveding Cecilie, Waage Anders, Minnema Monique C, Troia Rosella, Cornelisse Petra, Zamagni Elena, Zander Thilo, Zweegman Sonja, Ludwig Heinz, Aquino Sara, van der Holt Bronno, Beksac Meral, Dimopoulos Meletios A, Wester Ruth, Hájek Roman, Gulbrandsen Nina, Gregersen Henrik, Morelli Annamaria, De Rosa Luca, Cafro AnneMaria, Gay Francesca, Dozza Luca, Pantani Lucia, Cavo Michele
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Sonneveld P, von dem Borne P, Durian M, Hájek R, Boersma R, Wu K, Morelli A, Aquino S, Ludwig H, Bos G, Levin M, Benevolo G, Pascarella A, Troia R, Caravita di Toritto T, Zander T, Boccadoro M, Spencer A, Carvalho S, Palmas A, Cafro A, Mandigers C, Minnema M, van Marwijk Kooy M, Mellqvist U, Gimsing P, Waage A, Specchia G, Driessen C, Broijl A, Andersen N, Patriarca F, Palumbo G, Zamagni E, van der Velden V, Oliva S, Zweegman S, van der Holt B, Dozza L, Dimopoulos M, Petrucci M, Pantani L, Beksac M, Gay F, Montefusco V, Galli M, Liberati A, Zambello R, Vincelli I, Offidani M, Ballanti S, Croockewit A, Grasso M, Ypma P, Pour L, Belotti A, Hansson M, Gamberi B, Maisnar V, Cavo M. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 2020; 7:e456-e468.
30.04.2020Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
30.04.2020Lancet Haematol 2020; 7:e456-e468
Sonneveld Pieter, von dem Borne Peter A, Durian Marc, Hájek Roman, Boersma Rinske, Wu Ka Lung, Morelli Anna Maria, Aquino Sara, Ludwig Heinz, Bos Gerard, Levin Mark-David, Benevolo Giulia, Pascarella Anna, Troia Rossella, Caravita di Toritto Tommaso, Zander Thilo, Boccadoro Mario, Spencer Andrew, Carvalho Susanna, Palmas Angelo, Cafro Anna Maria, Mandigers Caroline, Minnema Monique, van Marwijk Kooy Marinus, Mellqvist Ulf-Henrik, Gimsing Peter, Waage Anders, Specchia Giorgina, Driessen Christoph, Broijl Annemiek, Andersen Niels Frost, Patriarca Francesca, Palumbo Giuseppe A, Zamagni Elena, van der Velden Vincent H J, Oliva Stefania, Zweegman Sonja, van der Holt Bronno, Dozza Luca, Dimopoulos Meletios A, Petrucci Maria Teresa, Pantani Lucia, Beksac Meral, Gay Francesca, Montefusco Vittorio, Galli Monica, Liberati Anna Marina, Zambello Renato, Vincelli Iolanda D, Offidani Massimo, Ballanti Stelvio, Croockewit Alexsandra, Grasso Mariella, Ypma Paula, Pour Ludek, Belotti Angelo, Hansson Markus, Gamberi Barbara, Maisnar Vladimir, Cavo Michele
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Zucca E, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei S, Ghielmini M, Kimby E, Novak U, Lohri A, Ferreri A, Rondeau S, Vanazzi A, Østenstad B, Mey U, Rauch D, Wahlin B, Hitz F, Hernberg M, Johansson A, de Nully Brown P, Hagberg H, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood 2019; 134:353-362.
17.05.2019Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
17.05.2019Blood 2019; 134:353-362
Zucca Emanuele, Zander Thilo, Bersvendsen Hanne, Bargetzi Mario, Mingrone Walter, Krasniqi Fatime, Dirnhofer Stefan, Hayoz Stefanie, Hawle Hanne, Vilei Simona Berardi, Ghielmini Michele, Kimby Eva, Novak Urban, Lohri Andreas, Ferreri Andrés J M, Rondeau Stephanie, Vanazzi Anna, Østenstad Bjørn, Mey Ulrich J M, Rauch Daniel, Wahlin Björn E, Hitz Felicitas, Hernberg Micaela, Johansson Ann-Sofie, de Nully Brown Peter, Hagberg Hans, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group
Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Schmidt A, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Heim D, Duchosal M, Driessen C, Betticher D, Bargetzi M, Renner C. Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2019; 149:w20031.
03.04.2019Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
03.04.2019Swiss Med Wkly 2019; 149:w20031
Samaras Panagiotis, Zander Thilo, Taverna Christian, Schmidt Adrian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Heim Dominik, Duchosal Michel A, Driessen Christoph, Betticher Daniel C, Bargetzi Mario, Renner Christoph
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
20.09.2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
20.09.2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer 2016
23.11.2016Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
23.11.2016Clin Lung Cancer 2016
Gautschi Oliver, Ochsenbein Adrian F, Mach Nicolas, Biaggi Christine, Schneider Martina, Zander Thilo, Froesch Patrizia, Peters Solange, Pless Miklos, Rauch Daniel, Cathomas Richard, Stahel Rolf A, Früh Martin, Betticher Daniel C, Zippelius Alfred, Matter-Walstra Klazien, Li Qiyu, Rothschild Sacha I
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2015; 145:w14100.
21.02.2015Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
21.02.2015Swiss Med Wkly 2015; 145:w14100
Samaras Panagiotis, Zander Thilo, Taverna Christian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Hess Urs, Heim Dominik, Duchosal Michel A, Betticher Daniel C, Bargetzi Mario, Renner Christoph
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Hofer S, Wick W, Zander T, Weder P, Roelcke U, Pichler J, Ochsenbein A, Marosi C, Lemke D, Huber U, Hottinger A, Greil R, Elandt K, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011; 50:630-5.
18.04.2011Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
18.04.2011Acta Oncol 2011; 50:630-5
Hofer Silvia, Wick Wolfgang, Zander Thilo, Weder Patrik, Roelcke Ulrich, Pichler Josef, Ochsenbein Adrian, Marosi Christine, Lemke Dieter, Huber Urs, Hottinger Andreas F, Greil Richard, Elandt Katarzyna, Weller Michael